Asia Pacific Radiopharmaceuticals Market
Tamanho do mercado em biliões de dólares
CAGR : %
Período de previsão |
2024 –2031 |
Tamanho do mercado (ano base ) | USD 1.76 Billion |
Tamanho do mercado ( Ano de previsão) | USD 2.73 Billion |
CAGR |
|
Principais participantes do mercado |
> Segmentação do mercado de radiofármacos da Ásia-Pacífico, por tipo (radiofarmacêuticos de diagnóstico e radiofarmacêuticos terapêuticos), aplicação (diagnóstico e terapêutico), tipo de medicamento (genéricos e de marca), fonte (reatores nucleares, ciclotrons e outros), utilizador final (hospitais, centros de diagnóstico , institutos de investigação do cancro, centros de cirurgia ambulatória e outros) - Tendências e previsões do sector para 2031.
Análise e dimensão do mercado de radiofármacos da Ásia-Pacífico
O mercado de implantes de córnea da Ásia-Pacífico é impulsionado por vários fatores, incluindo a crescente prevalência de doenças da córnea, um crescente envelhecimento da população, avanços na tecnologia, aumento da procura por procedimentos minimamente invasivos, aumento da consciencialização sobre o transplante de córnea, iniciativas e financiamento governamentais, o aumento da adoção de lentes híbridas e tóricas, a crescente popularidade dos procedimentos de cross-linking, a expansão das indicações para implantes de córnea e um cenário competitivo que promove a inovação. Estes factores estão a impulsionar colectivamente a procura de implantes de córnea, particularmente nos países desenvolvidos, à medida que os pacientes procuram tratamentos eficazes para distúrbios e condições de visão como o ceratocone, a distrofia de Fuchs e a ceratopatia bolhosa pseudofácica.
A Data Bridge Market Research analisa que o mercado de radiofármacos da Ásia-Pacífico deverá atingir os 2,73 mil milhões de dólares até 2031, contra 1,76 mil milhões de dólares em 2023, crescendo com um CAGR de 5,7% durante o período de previsão de 2024 a 2031.
Métrica de reporte |
Detalhes |
Período de previsão |
2024 a 2031 |
Ano base |
2023 |
Anos históricos |
2022 (personalizável 2016-2021) |
Unidades Quantitativas |
Receita em biliões de dólares |
Segmentos cobertos |
Tipo (Radiofármacos Diagnósticos e Radiofármacos Terapêuticos), Aplicação (Diagnóstico e Terapêutico), Tipo de Medicamento (Genéricos e de Marca), Fonte (Reatores Nucleares, Ciclotrons e outros), Utilizador Final (Hospitais, Centros de Diagnóstico, Institutos de Investigação do Cancro , Centros Cirúrgicos Ambulatório e outros) |
Países abrangidos |
China, Japão, Austrália, Coreia do Sul, Singapura, Índia, Indonésia, Filipinas, Malásia, Vietname e resto da Ásia-Pacífico |
Participantes do mercado abrangidos |
Cardinal Health, Advanced Accelerator Applications, Lantheus, Curium, GE HealthCare, Jubilant Radiopharma, (A Jubilant Pharma Company), Ansto, Eli Lilly And Company, Bayer AG, Siemens Healthcare Gmbh, China, lsotope & Radiation Corporation, Bracco, NTP, Eckert & Ziegler, Eczacıbaşı-Monrol, IBA Worldwide, BWX Technologies. Inc, Isotope JSC, Sterigenics US, LLC entre outros. |
Definição de mercado
A Radiopharmaceuticals contains a radioactive substance in association with one or more ingredients and that is intended to diagnose, stage a disease, monitor treatment, or provide therapy.. Radiopharmaceuticals include a group of radioactive agents used for either diagnostic or therapeutic interventions. Radiopharmaceuticals are the pharmaceuticals that incorporate a radionuclide. Most radiopharmaceuticals are a combination of a radioactive nuclide or radionuclide, and a biologically active molecule or drug that acts as a carrier and determines localization and biodistribution.
Asia-Pacific Radiopharmaceuticals Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
The Growing Demand for Radiopharmaceuticals in Diagnostics and Clinical Use
Radiopharmaceuticals have become essential in helping to diagnose organs and treat pathological disorders. They are utilized in diagnostic imaging and radiotherapy. Diagnostic radiopharmaceuticals possess no pharmacological effects and their administration is also not considered to be associated with relevant clinical side effects.
The number of radiopharmaceuticals in clinical use is rapidly growing, thus, allowing the medical community better access to detail information on the characteristics of the different types of tumors. Radionuclides are also gaining importance by providing palliative and curative treatment for an increasing number of malignant diseases.
For instance,
- In February 2024 , According to the Article published by International Atomic Energy Agency, Radiopharmaceuticals are used in diagnosis by administering radioactive compounds that emit gamma photons, which penetrate the body and are detected by external cameras to produce images of target tissues or organs. These images help in detecting tumors, assessing organ function, and diagnosing conditions like cancer and cardiovascular diseases. Unlike X-rays, a waiting period is often required for the radiopharmaceutical to reach its target, enabling precise imaging
The Increasing Need for Pharmaceutical Products Across Varied Therapeutic Areas
The growing cases of new diseases across the globe are a major concern for healthcare providers. Pharma and biopharmaceuticals companies are putting in everyday effort to tackle the challenge associated with various diseases. The increasing interest of market players willing to provide a wide range of radiopharmaceuticals products to be used in a different formulation pushes the market growth.
The increasing disease prevalence which is related to age, population type, genetic inheritance, and chronic infectious disease spreading worldwide is the major factor owing to the increasing demand for radiopharmaceutical products. They have been described for the diagnosis of inflammatory chronic diseases and several peptides, receptor ligands and monoclonal antibodies have been radiolabeled which allows in-vivo visualization of inflammatory processes at a cellular and molecular level.
For instance,
- In February 2019, as per NCBI article, a number of recent developments suggest that radiopharmaceutical therapy is poised to emerge as an important and widely-recognized therapeutic modality which have the ability to deliver cytotoxic radiation to tumor cells without causing prohibitive normal tissue toxicity
Opportunity
The Rising Research and Development Expenditure of Radiopharmaceuticals
Technological advancements include enhancing the stability and strength of traditional pharmaceuticals. The biotechnology and pharma companies are continuously investing in research and development to offer innovative services for diagnostics as well as medications to the customers and enhance their market presence. Radiopharmaceuticals play a dynamic role in clinical development. While the diagnostic industry is in a constant state of fluctuation due to the implementation of new technologies in the market, the pharmaceutical and biotechnology industries continue to increase due to enhanced investment in radiopharmaceuticals companies along with mergers and acquisitions adoption of innovation in imaging technologies to support clinical trials for various diseases.
Restraint/Challenge
- Potential Risks Associated with Radiopharmaceuticals
Chronic inhalation exposure to uranium and radon in humans has been linked to respiratory effects, such as chronic lung disease, while radium exposure has resulted in acute leukopenia, anaemia, necrosis of the jaw, and other effects. The radioactive element radium looks like a calcium molecule which gets incorporated into areas of the body where bone turnover is high in amount such as areas of organs where cancer is growing, apart from this few procedural risks are also involved with the radiopharmaceuticals.
Recent Developments
• In October 2022, Cardinal Health was recognized by Forbes as one of America's Best Large Employers company 2022 through an independent survey taken by approximately 60,000 American employees working for U.S. companies. The company believes this will inspire them and will give motivation to their employees
- In December 2022, Novartis received the European Commission approval for Pluvicto as the first targeted radioligand therapy for treatment of prostate cancer. The company believes that this will help in advancing a broad portfolio of radioligand therapies to treat cancer
- Em agosto de 2024, a Lantheus Holdings, Inc. (“Lantheus”), a empresa líder focada em radiofármacos empenhada em permitir aos médicos encontrar, combater e seguir doenças para oferecer melhores resultados aos pacientes, anunciou hoje que Oliver Sartor, MD , Diretor de Ensaios Radiofarmacêuticos e Professor de Oncologia Médica na Clínica Mayo em Rochester, Minnesota, fará uma apresentação oral, incluindo dados clínicos adicionais da leitura inicial do PNT2002 de dezembro de 2023, durante a Reunião Anual da Sociedade Europeia de Oncologia Médica (ESMO) em Barcelona, no domingo, 15 de setembro.
- Em julho de 2024, a ANSTO e a Universidade de Wollongong desenvolveram um dispositivo Quad-MOSFET para controlo de qualidade em tempo real na terapia de captura de neutrões de boro. Esta ferramenta inovadora aumenta a precisão ao distinguir os níveis de energia dos neutrões, melhorando a segurança e a eficácia do tratamento do cancro
Âmbito do mercado de radiofármacos da Ásia-Pacífico
O mercado de radiofármacos da Ásia-Pacífico está segmentado em oito segmentos notáveis com base no tipo, aplicação, tipo de medicamento, origem e utilizador final. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e as diferenças nos seus mercados-alvo.
Tipo
- Radiofármacos Diagnósticos
- Radiofármacos Terapêuticos
Com base no tipo, o mercado de radiofármacos da Ásia-Pacífico está segmentado em radiofármacos de diagnóstico e radiofarmacêuticos terapêuticos.
Aplicação
- Diagnóstico
- Terapêutico
Com base na aplicação, o mercado de radiofármacos da Ásia-Pacífico está segmentado em diagnóstico e terapêutico.
Tipo de droga
- Com marca
- Genéricos
Com base no tipo de medicamento, o mercado de radiofármacos da Ásia-Pacífico está segmentado em genéricos e de marca.
Fonte
- Reatores Nucleares
- Ciclotrons
- Outros
Com base na fonte, o mercado radiofarmacêutico da Ásia-Pacífico está segmentado em reatores nucleares, ciclotrões, entre outros.
Utilizador final
- Hospitais
- Centros de Diagnóstico
- Institutos de Investigação do Cancro
- Centros Cirúrgicos Ambulatoriais
- Outros
Com base no utilizador final, o mercado de radiofármacos da Ásia-Pacífico está segmentado em hospitais, centros de diagnóstico, institutos de investigação do cancro, centros de cirurgia ambulatória , entre outros.
Análise/perspetivas regionais do mercado radiofarmacêutico da Ásia-Pacífico
O mercado de radiofármacos da Ásia-Pacífico é analisado e são fornecidos insights e tendências do tamanho do mercado com base no tipo, aplicação, tipo de medicamento, fonte e utilizador final.
Os países abrangidos neste relatório de mercado são a China, o Japão, a Austrália, a Coreia do Sul, Singapura, a Índia, a Indonésia, as Filipinas, a Malásia, o Vietname e o resto da Ásia-Pacífico.
Prevê-se que a China domine o mercado da Ásia-Pacífico devido à sua grande população, ao aumento dos gastos com os cuidados de saúde, à expansão da indústria farmacêutica, à crescente consciencialização dos consumidores e à procura de tratamentos, juntamente com uma infra-estrutura de saúde em desenvolvimento e uma prevalência crescente.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas da Ásia-Pacífico e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas domésticas e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Análise do panorama competitivo e da quota de mercado de radiofármacos da Ásia-Pacífico
O panorama competitivo do mercado radiofarmacêutico da Ásia-Pacífico fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença regional, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produtos, largura e amplitude do produto, e domínio da aplicação. Os dados fornecidos acima estão apenas relacionados com o foco das empresas no mercado radiofarmacêutico da Ásia-Pacífico.
Alguns dos principais players que operam no mercado de radiofármacos da Ásia-Pacífico são a Cardinal Health, Advanced Accelerator Applications, Lantheus, Curium, GE HealthCare, Jubilant Radiopharma, (A Jubilant Pharma Company), Ansto, Eli Lilly And Company, Bayer AG, Siemens Healthcare Gmbh, China, lsotope & Radiation Corporation, Bracco, NTP, Eckert & Ziegler, Eczacıbaşı-Monrol, IBA Worldwide, BWX Technologies. Inc, Isotope JSC, Sterigenics US, LLC entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC RADIOPHARMACEUTICALS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET TESTING TYPE COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
5 REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE
6.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS
6.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS
6.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS
6.3 OPPORTUNITIES
6.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS
6.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION
6.4 CHALLENGES
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS
6.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE
7 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 BRANDED
7.3 GENERICS
8 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS
8.2.1 PET RADIOPHARMACEUTICALS
8.2.1.1 F-18
8.2.1.2 RU-82
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS
8.2.2 SPECT RADIOPHARMACEUTICALS
8.2.2.1 TECHNETIUM-99M
8.2.2.2 GALLIUM-67
8.2.2.3 IODINE-123
8.2.2.4 THALLIUM-201
8.2.2.5 OTHER SPECT ISOTOPES
8.3 THERAPEUTIC RADIOPHARMACEUTICALS
8.3.1 BRACHYTHERAPY ISOTOPES
8.3.1.1 IODINE-125
8.3.1.2 PALLADIUM-103
8.3.1.3 CESIUM-131
8.3.1.4 IRIDIUM-192
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES
8.3.2 BETA EMITTERS
8.3.2.1 IODINE-131
8.3.2.2 LUTHETIUM-177
8.3.2.3 SAMARIUM-153
8.3.2.4 YTTRIUM-90
8.3.2.5 RHENIUM-186
8.3.2.6 OTHER BETA EMITTERS
8.3.3 ALPHA EMITTERS
8.3.3.1 RA-223
8.3.3.2 OTHERS
9 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 DIAGNOSTIC
9.2.1 ONCOLOGY
9.2.2 CARDIOLOGY
9.2.3 NEUROLOGY
9.2.4 BONE SCANS
9.2.5 THYROID APPLICATIONS
9.2.6 PULMONARY SCANS
9.2.7 OTHERS
9.3 THERAPEUTIC
9.3.1 THYROID INDICATIONS
9.3.2 BONE METASTASIS
9.3.3 LYMPHOMA
9.3.4 ENDOCRINE TUMORS
9.3.5 OTHER INDICATIONS
10 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 NUCLEAR REACTORS
10.3 CYCLOTRONS
10.4 OTHERS
11 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 PUBLIC
11.2.2 PRIVATE
11.2.2.1 DIAGNOSTIC CENTERS
11.2.2.2 CANCER RESEARCH INSTITUTES
11.2.2.3 AMBULATORY SURGICAL CENTERS
11.2.2.4 OTHERS
12 APAC RADIOPHARMACEUTICALS MARKET, BY COUNTRY
12.1 ASIA-PACIFIC
13 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 CARDINAL HEALTH
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 LANTHEUS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 CURIUM
15.4.1 COMPANY SNAPSHOT
15.4.2 PRODUCT PORTFOLIO
15.4.3 RECENT DEVELOPMENT
15.5 GE HEALTHCARE
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ANSTO
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT UPDATES
15.7 BAYER AG
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 BRACCO
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BWX TECHNOLOGIES. INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 CHINA ISOTOPE & RADIATION CORPORATION
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 ELI LILLY AND COMPANY
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 ECKERT & ZIEGLER
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 GLOBAL MEDICAL SOLUTIONS
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 ECZACIBAŞI-MONROL
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 IBA WORLDWIDE
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 ISOTOPE JSC
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 MALLINCKRODT PHARMACEUTICALS
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT UPDATES
15.19 NTP
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 SIEMENS HEALTHCARE GMBH
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENT
15.21 STERIGENICS U.S., LLC – A SOTERA HEALTH COMPANY
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tabela
TABLE 1 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 2 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 3 ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 5 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 6 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 7 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 8 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 9 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 10 ASIA-PACIFIC THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 11 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 13 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 14 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 15 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 16 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 17 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 18 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 19 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 20 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 21 ASIA-PACIFIC DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 ASIA-PACIFIC THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 24 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 25 ASIA-PACIFIC HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 27 CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 CHINA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 29 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 30 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 31 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 32 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 34 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 35 CHINA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 36 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 38 100
TABLE 39 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 40 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 41 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 42 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 43 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 45 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 46 CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 47 CHINA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 CHINA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 CHINA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 50 CHINA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 51 CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 52 CHINA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 54 AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 55 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 57 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 58 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 59 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 60 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 61 AUSTRALIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 64 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 65 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 67 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 68 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 70 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 71 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 72 AUSTRALIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 73 AUSTRALIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 75 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 76 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 77 AUSTRALIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 78 JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 82 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 83 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 85 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 86 JAPAN THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 89 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 90 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 92 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 93 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 94 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 95 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 96 JAPAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 97 JAPAN DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 JAPAN THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 JAPAN RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 100 JAPAN RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 101 JAPAN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 102 JAPAN HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 SOUTH KOREA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 106 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 107 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 108 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 110 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 111 SOUTH KOREA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 112 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 113 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 114 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 115 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 117 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 118 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 119 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 120 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 121 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 122 SOUTH KOREA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 123 SOUTH KOREA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 125 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 126 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 127 SOUTH KOREA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 SINGAPORE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 132 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 133 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 135 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 136 SINGAPORE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 139 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 140 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 141 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 142 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 143 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 145 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 146 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 147 SINGAPORE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 148 SINGAPORE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 150 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 151 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 152 SINGAPORE HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 153 INDIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 INDIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 155 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 157 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 158 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 159 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 160 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 161 INDIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 163 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 164 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 165 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 167 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 168 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 170 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 171 INDIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 172 INDIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 INDIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 INDIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 175 INDIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 176 INDIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 177 INDIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 178 INDONESIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 180 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 182 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 183 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 184 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 185 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 186 INDONESIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 187 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 189 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 190 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 192 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 193 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 194 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 195 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 196 INDONESIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 197 INDONESIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 INDONESIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 199 INDONESIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 200 INDONESIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 201 INDONESIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 202 INDONESIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 204 PHILIPPINES DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 205 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 207 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 208 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 209 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 210 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 211 PHILIPPINES THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 212 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 213 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 214 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 215 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 217 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 218 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 219 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 220 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 221 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 222 PHILIPPINES DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 PHILIPPINES THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 225 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 226 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 227 PHILIPPINES HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 THAILAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 THAILAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 231 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 232 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 233 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 234 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 235 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 236 THAILAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 237 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 239 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 240 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 241 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 242 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 243 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 244 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 245 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 246 THAILAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 247 THAILAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 THAILAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 THAILAND RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 250 THAILAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 251 THAILAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 252 THAILAND HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 253 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 254 MALAYSIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 257 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 258 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 259 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 260 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 261 MALAYSIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 262 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 263 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 264 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 265 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 267 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 268 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 269 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 270 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 271 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 272 MALAYSIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 MALAYSIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 274 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 275 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 276 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 277 MALAYSIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 278 VIETNAM RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 279 VIETNAM DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 282 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 283 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 284 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 285 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 286 VIETNAM THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 287 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 288 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 289 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 290 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 291 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 292 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 293 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 294 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 295 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 296 VIETNAM RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 297 VIETNAM DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 298 VIETNAM THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 299 VIETNAM RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 300 VIETNAM RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 301 VIETNAM RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 302 VIETNAM HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 303 REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
Lista de Figura
FIGURE 1 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 11 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET:
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 THE RISING PREVALENCE OF CHRONIC DISEASES IS EXPECTED TO DRIVE THE ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET IN THE FORECAST PERIOD
FIGURE 15 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET IN 2024 & 2031
FIGURE 16 DROC ANALYSIS
FIGURE 17 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, 2023
FIGURE 18 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 19 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 20 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, 2023
FIGURE 22 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 23 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 24 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2023
FIGURE 26 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2024-2031 (USD MILLION)
FIGURE 27 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 28 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2023
FIGURE 30 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2024-2031 (USD MILLION)
FIGURE 31 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, CAGR (2024-2031)
FIGURE 32 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, 2023
FIGURE 34 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 35 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, CAGR (2024-2031)
FIGURE 36 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 APAC RADIOPHARMACEUTICALS MARKET BY SNAPSHOT
FIGURE 38 AISA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2023 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.